BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10320045)

  • 1. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection.
    Barnard DL; Sidwell RW; Xiao W; Player MR; Adah SA; Torrence PF
    Antiviral Res; 1999 Apr; 41(3):119-34. PubMed ID: 10320045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.
    Cirino NM; Li G; Xiao W; Torrence PF; Silverman RH
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1937-42. PubMed ID: 9050883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.
    Player MR; Barnard DL; Torrence PF
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8874-9. PubMed ID: 9671772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.
    Leaman DW; Longano FJ; Okicki JR; Soike KF; Torrence PF; Silverman RH; Cramer H
    Virology; 2002 Jan; 292(1):70-7. PubMed ID: 11878909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.
    Jairath S; Vargas PB; Hamlin HA; Field AK; Kilkuskie RE
    Antiviral Res; 1997 Feb; 33(3):201-13. PubMed ID: 9037376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.
    Xu Z; Kuang M; Okicki JR; Cramer H; Chaudhary N
    Antiviral Res; 2004 Mar; 61(3):195-206. PubMed ID: 15168801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.
    Torrence PF
    Curr Opin Mol Ther; 1999 Jun; 1(3):307-15. PubMed ID: 11713795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense.
    Player MR; Maitra RK; Silverman RH; Torrence PF
    Antivir Chem Chemother; 1998 May; 9(3):225-31. PubMed ID: 9875401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of selective modifications to a 2',5'-oligoadenylate-3',5'-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L.
    Xiao W; Li G; Maitra RK; Maran A; Silverman RH; Torrence PF
    J Med Chem; 1997 Apr; 40(8):1195-200. PubMed ID: 9111293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recruiting the 2-5A system for antisense therapeutics.
    Torrence PF; Xiao W; Li G; Cramer H; Player MR; Silverman RH
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):203-6. PubMed ID: 9212911
    [No Abstract]   [Full Text] [Related]  

  • 11. 2-5A antisense treatment of respiratory syncytial virus.
    Leaman DW
    Curr Opin Pharmacol; 2005 Oct; 5(5):502-7. PubMed ID: 16081320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling gene expression with 2-5A antisense.
    Leaman DW; Cramer H
    Methods; 1999 Jul; 18(3):252-65. PubMed ID: 10454983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy of respiratory syncytial virus by 2-5A antisense.
    Cramer H; Okicki JR; Kuang M; Xu Z
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):497-501. PubMed ID: 16247978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of the antisense oligonucleotides carrying the modified 2-5A molecules at their 5'-termini and their properties.
    Ueno Y; Kato Y; Okatani S; Kitade Y
    Nucleic Acids Res Suppl; 2002; (2):45-6. PubMed ID: 12903097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras.
    Maran A; Maitra RK; Kumar A; Dong B; Xiao W; Li G; Williams BR; Torrence PF; Silverman RH
    Science; 1994 Aug; 265(5173):789-92. PubMed ID: 7914032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2'-O-methylated 2-5A-antisense oligonucleotides.
    Cramer H; Player MR; Torrence PF
    Bioorg Med Chem Lett; 1999 Apr; 9(7):1049-54. PubMed ID: 10230638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNAzyme].
    Zhao CA; Zhao XD; Yu HG; Wu YP; Yang XQ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):594-7. PubMed ID: 14744382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.
    Thillier Y; Stevens SK; Moy C; Taylor J; Vasseur JJ; Beigelman L; Debart F
    Bioorg Med Chem; 2013 Sep; 21(17):5461-9. PubMed ID: 23810677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes.
    Barnard DL; Hill CL; Gage T; Matheson JE; Huffman JH; Sidwell RW; Otto MI; Schinazi RF
    Antiviral Res; 1997 Mar; 34(1):27-37. PubMed ID: 9107383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.
    Adah SA; Bayly SF; Cramer H; Silverman RH; Torrence PF
    Curr Med Chem; 2001 Aug; 8(10):1189-212. PubMed ID: 11472236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.